A clinical study to compare the effects of Citrakadi tablet & standard medicine (combination of Myo-inositol 550mg & D-chiro inositol 13.8 mg tablet) in reducing HOMA-IR in patients with Polycystic Ovarian Syndrome

Efficacy of Citrakadi Tablet on HOMA-IR in Polycystic Ovarian Syndrome - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082988

Enrollment

Registered

2025-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age group between 18-45 years with HOMA IR 2.5 or above Satisfying any two of the features as per Rotterdam criteria i.e. Irregular menstrual cycles, hyperandrogenism (features like excess hair growth), presence of cyst in USG Willing to participate in the study

Exclusion criteria

Exclusion criteria: Pregnant and lactating mother Diagnosed case of Irregular menstrual bleeding caused by conditions such as uterine polyps or fibroids Diagnosed case of Uncontrolled hypo or hyperthyroidism Post hysterectomy or endometrial ablation HbA1c greater than 10

Design outcomes

Primary

Measure	Time frame
Homeostasis model assessment for insulin resistance (HOMA-IR)Timepoint: baseline, 90 days	—

Secondary

Measure	Time frame
Waist circumference (WC) HbA1c TG LDL-C HDL-C BMI USGTimepoint: Baseline,91- day	—

Countries

India

Contacts

Public ContactDr Asha Sreedhar

Govt Ayurveda College Thiruvananthapuram

drindulekha@gmail.com9446553068

Outcome results